Search
Vidarabine
go.drugbank.com/drugs/DB00194ApprovedWithdrawnIt has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the
Indalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIt was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions.
Benzthiazide
go.drugbank.com/drugs/DB00562ApprovedThiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. … Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Lorazepam
go.drugbank.com/drugs/DB00186ApprovedInvestigational[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation. It is the primary ingredient of the RSV vaccine mRESVIA. mRESVIA was first approved in the EU and US in 2024...
Safrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnIn 1960, it was used as an antidepressant but it is now discontinued.
Pralsetinib
go.drugbank.com/drugs/DB15822ApprovedInvestigationalIt is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]
Volixibat
go.drugbank.com/drugs/DB13914InvestigationalIf approved for use, it will be the first available agent for the treatment of NASH. … Volixibat is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein primarily expressed by enterocytes of the ileum.
Remdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigational[L18438] Remdesivir is currently marketed under the trademark name VEKLURY by Gilead Sciences Inc.[L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues.